There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Pliant Therapeutics (PLRX – Research Report) and Trevena (TRVN – Research Report) with bullish sentiments.
Pliant Therapeutics (PLRX)
H.C. Wainwright analyst Ed Arce maintained a Buy rating on Pliant Therapeutics today and set a price target of $36.00. The company’s shares closed last Wednesday at $15.33.
According to TipRanks.com, Arce is a 4-star analyst with an average return of
Pliant Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $40.55, a 178.5% upside from current levels. In a report issued on May 6, Wells Fargo also maintained a Buy rating on the stock with a $41.00 price target.
See today’s best-performing stocks on TipRanks >>
Trevena (TRVN)
JMP Securities analyst Jason Butler reiterated a Buy rating on Trevena today and set a price target of $3.00. The company’s shares closed last Wednesday at $0.41, close to its 52-week low of $0.30.
According to TipRanks.com, Butler ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Trevena with a $6.00 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on PLRX:
- Pliant Therapeutics announces results from Phase 2a trial of bexotegrast
- Pliant Therapeutics Announces Positive Topline Data from a Phase 2a Collagen PET Imaging Clinical Trial of Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis
- Pliant Therapeutics price target lowered to $45 from $54 at RBC Capital
- Pliant Therapeutics price target raised to $48 from $47 at Oppenheimer
- Pliant Therapeutics price target lowered to $36 from $48 at H.C. Wainwright
